# COLchicine and Non-enteric Coated Aspirin in the Cardiovascular Outcomes Trial of Patients With Type 2 Diabetes

Study · id `cardio:ct-nct05633810` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05633810](<https://clinicaltrials.gov/study/NCT05633810>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05633810

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 10000 participants.

## Technical summary

Registry record NCT05633810. Randomized; quadruple masking; primary purpose prevention. Start 2022-12-21 (actual); primary completion 2027-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 10000 participants (planned count; ClinicalTrials.gov record NCT05633810, source copy `cardio:ctgov-nct05633810-2026-10-06`, retrieved 2026-10-26)
- Started: 2022-12-21 (actual) (ClinicalTrials.gov record NCT05633810, source copy `cardio:ctgov-nct05633810-2026-10-06`, retrieved 2026-10-26)
- Primary completion: 2027-12 (anticipated) (ClinicalTrials.gov record NCT05633810, source copy `cardio:ctgov-nct05633810-2026-10-06`, retrieved 2026-10-26)
- Completion: 2027-12 (anticipated) (ClinicalTrials.gov record NCT05633810, source copy `cardio:ctgov-nct05633810-2026-10-06`, retrieved 2026-10-26)
- Countries: Australia; Canada; Denmark; Finland; France; Greece; Italy; Portugal (ClinicalTrials.gov record NCT05633810, source copy `cardio:ctgov-nct05633810-2026-10-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05633810-2026-10-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: COLchicine and Non-enteric Coated Aspirin in the Cardiovascular Outcomes Trial of Patients With Type 2 Diabetes
- Acronym: COLCOT-T2D
- Condition: Diabete Type 2
- Condition: Cardiovascular Diseases
- Intervention (Drug): Aspirin
- Intervention (Drug): Aspirin Placebo
- Intervention (Drug): Colchicine
- Intervention (Drug): Colchicine Placebo
- Lead sponsor: Montreal Heart Institute
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry intervention name matches this record: Aspirin (`core:aspirin`)
- Registry intervention name matches this record: Colchicine (`cardio:colchicine`)
- Registry lists this organization as the lead sponsor: Montreal Heart Institute (`cardio:org-montreal-heart-institute`)

## Provenance

Content hash: ae0cc9b370544816908de8aae1fa1dfd07cfa4d9656ae79b49b2d464efb647d2
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
